Claims for Patent: 6,838,252

Summary for Patent: 6,838,252

Title:	Inhibitors of proteasomal activity for stimulating hair growth
Abstract:	The present invention relates to compounds that inhibit the activity of the proteasome or the production of proteasomal proteins and promote the production of hair follicles and are thus useful in stimulating hair growth, including hair density, in subject where this is desirable.
Inventor(s):	Mundy; Gregory R. (San Antonio, TX), Garrett; I. Ross (San Antonio, TX), Rossini; Jorge Gianny (San Antonio, TX)
Assignee:	OsteoScreen, Inc. (San Antonio, TX)
Application Number:	10/052,832
Patent Claims:	1. A method to treat a mammalian subject for a condition benefited by stimulating hair growth which method comprises administering to said mammalian subject in need of such treatmeant an effective amount of a compound that inhibits protesomal activity. 2. The method of claim 1, wherein the compound inhibits the trypsin-like of PGPH activity of the proteasome. 3. The method of claim 1, wherein the compound inhibits the chymotrypsin-like activity of the proteasome. 4. The method of claim 3, wherein the compound is a peptide having at least 3 amino acids and a C-terminal functional group that reacts with the threonine residue of the chymotrypsin-like catalytic site of the proteasome. 5. The method of claim 4, wherein the C-terminal functional group is selected from the group consisting of an epoxide, a --B(OR).sub.2 group, a --S(OR).sub.2 group and a --SOOR group, wherein R is H, an alkyl (C.sub.1-6) or an aryl (C.sub.1-6). 6. The method of claim 5, wherein the functional group is an epoxide that forms a morpholino ring with the theonine residue of the chymotrypsin-like catalytic site of the proteasome. 7. The method of claim 3, wherein the peptide is a peptide .alpha.',.beta.'-epoxyketone. 8. The method of claim 7, wherein the peptide .alpha.',.beta.'-epoxyketone has at least 4 amino acids. 9. The method of claim 7, wherein the c-terminus amino acid of the peptide .alpha.',.beta.'-epoxyketone is a hydrophobic amino acid. 10. The method of claim 9, wherein the hydrophobic amino acid is leucine or phenylalanine. 11. The method of claim 7, wherein the peptide .alpha.',.beta.'-epoxyketone has the following formula: ##STR34## wherein each of R, R.sup.1, R.sup.2 and R.sup.3 is a hydrophobic substituent. 12. The method of claim 11, wherein each of R, R.sup.1, R.sup.2, and R.sup.3 is independently selected from the group consisting of ##STR35## 13. The method of claim 11, wherein R.sup.2 and R.sup.3 are ##STR36## and the compound is selected from the group consisting of ##STR37## 14. The method of claim 11, wherein the peptide .alpha.',.beta.'-epoxyketone has the following stereo-configuration: ##STR38## 15. The method of claim 7, wherein the peptide .alpha.',.beta.'-epoxyketone has the following formula: ##STR39## wherein R is selected from the group consisting of ##STR40## 16. The method of claim 15, wherein the peptide .alpha.',.beta.'-epoxyketone has the following stereo-configuration: ##STR41## 17. The method of claim 16, wherein the peptide .alpha.',.beta.'-epoxyketone is ##STR42## 18. The method of claim 3, wherein the compound is selected from the group consisting of ##STR43## pyrazylcarbonyl-Phe-Leu-Boronate (PS-341), tri-leucine vinyl sulfone (NLVS), N-carbobenzoyl-Ile-Glu-(OtBu)-Ala-Leu-CHO (PSI) epoxide, and lactacystin. 19. The method of claim 3, wherein the compound has the following formula: ##STR44## wherein the warhead reacts irreversibly with the catalytic chymotrypsin site of the proteasome; A is independently CO--NH or isostereomer thereof; R is independently a hydrocarbyl; X is a polar group; and n=0-2. 20. The method of claim 19, wherein R contains a substituted group selected from the group consisting of a halo group, --OR, --SR, --NR.sub.2, .dbd.O, --COR, --OCOR, --NHCOR, --NO.sub.2, --CN, and --CF.sub.3. 21. The method of claim 19, wherein X is presented. 22. The method of claim 1, wherein said subject is a human. 23. The method of claim 1, wherein said condition to be treated is selected from the group consisting of male pattern baldness, alopecia caused by chemotherapy, hair thinning due to aging, and genetic disorders. 24. The method of claim 1, wherein said subject is a non-human mammal. 25. The method of claim 24, wherein said hair growth provides additional protection from cold temperatures. 26. The method of claim 1, wherein said hair growth is due to thickened hair sheath diameter, increased hair diameter, differentiation of quiescent hair follicles into more mature forms, increased rate of growth in hair length and/or thickness, or the appearance of proliferation of new hair follicles. 27. The method of claim 1, wherein said compound is co-administered with an agent promoting skin tissue growth or infiltration. 28. The method of claim 27, wherein said agent is selected from the group consisting of an epidermal growth factor, a fibroblast growth factor, a platelet-derived growth factor, a transforming growth factor, a parathyroid hormone, a leukemia inhibitory factor, and an insulin-like growth factor.

Details for Patent 6,838,252

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2020-10-23